Preventable Vaccines

Global Preventable Vaccines Market to Reach US$92.9 Billion by 2030

The global market for Preventable Vaccines estimated at US$86.9 Billion in the year 2024, is expected to reach US$92.9 Billion by 2030, growing at a CAGR of 1.1% over the analysis period 2024-2030. Live / Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$34.1 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$23.6 Billion While China is Forecast to Grow at 2.1% CAGR

The Preventable Vaccines market in the U.S. is estimated at US$23.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.7 Billion by the year 2030 trailing a CAGR of 2.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Global Preventable Vaccines Market - Key Trends and Drivers Summarized

Preventable vaccines are essential tools in the global health arsenal, designed to protect individuals and populations from infectious diseases by stimulating the immune system to recognize and fight pathogens effectively. These biological preparations introduce a harmless form of a disease-causing microorganism or one of its components into the body, prompting the immune system to respond and build immunity without causing the actual disease. This mechanism enables the immune system to respond more rapidly and effectively should the individual ever be exposed to the real pathogen. The routine vaccine schedule, which includes immunizations against diseases such as measles, mumps, rubella, diphtheria, and pertussis, is a cornerstone of public health policy worldwide. Vaccination has led to the eradication or significant reduction of many life-threatening diseases and continues to be a critical strategy in preventing outbreaks and epidemics.

The development and distribution of vaccines involve complex research and rigorous testing to ensure safety and efficacy before they are approved for public use. Over the years, vaccine technology has evolved from live-attenuated and inactivated forms to more sophisticated subunit, recombinant, conjugate, and mRNA vaccines. Each type is tailored to fight different pathogens in the most effective way possible, with newer technologies, such as mRNA vaccines, offering rapid development in response to emerging infectious diseases like COVID-19. Furthermore, the advent of vaccine platforms that can be quickly adapted to new pathogens has revolutionized the field, particularly in response to pandemics. Besides human health, vaccines are also crucial in veterinary practices, protecting livestock from diseases and thereby supporting food security and agricultural economies.

The growth in the preventable vaccines market is driven by several factors, including technological advancements in vaccine development, an increase in government and private funding for immunization programs, and a heightened awareness of the importance of vaccinations. Technological innovations have led to more effective and safer vaccines, with developments in adjuvants and delivery systems improving the immune response and reducing side effects. The global expansion of routine immunization programs, supported by international health organizations and governments, has increased the demand for vaccines, especially in underdeveloped and developing regions. Additionally, consumer behavior has shifted significantly in recent years, with a growing preference for preventive healthcare measures, further spurred by the COVID-19 pandemic’s demonstration of the critical role of vaccinations in controlling infectious diseases. The market`s expansion is also facilitated by the rise in travel and migration, which increases the exposure to different pathogens, thereby boosting the need for broader immunization coverage. This dynamic market is expected to continue growing as new vaccine technologies and international health initiatives expand to meet the challenges of existing and emerging infectious diseases.

 

SCOPE OF STUDY:

The report analyzes the Preventable Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Vaccine Type (Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Other Vaccine Types); Disease Type (Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease, Influenza Disease, Measles & Rubella Disease, Other Disease Types); Distribution Channel (Public Distribution Channel, Private Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

• AstraZeneca PLC
• Bharat Biotech International Ltd.
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co., Ltd.
• Emergent BioSolutions, Inc.
• GSK Plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Novavax, Inc.
• Pfizer, Inc.
• Roche CustomBiotech
• Sanofi SA
• Serum Institute of India Pvt., Ltd.
• Takeda Pharmaceutical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.